|
JPH0757213A
(ja)
*
|
1993-08-13 |
1995-03-03 |
Matsushita Electric Ind Co Ltd |
磁気ヘッド
|
|
US6183744B1
(en)
*
|
1997-03-24 |
2001-02-06 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
|
US8383081B2
(en)
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
|
US7829064B2
(en)
*
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
|
KR20020020730A
(ko)
*
|
1999-06-09 |
2002-03-15 |
오트리브 데이비스 더블유 |
Ｂ-세포를 표적하는 항체를 이용한 자가면역질환의 면역치료
|
|
US20110045005A1
(en)
|
2001-10-19 |
2011-02-24 |
Craig Crowley |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
US8435529B2
(en)
|
2002-06-14 |
2013-05-07 |
Immunomedics, Inc. |
Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
|
|
US7591994B2
(en)
*
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US20160279239A1
(en)
*
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
|
US8361464B2
(en)
|
2002-03-01 |
2013-01-29 |
Immunomedics, Inc. |
Anthracycline-Antibody Conjugates for Cancer Therapy
|
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
|
ATE477276T1
(de)
*
|
2002-03-01 |
2010-08-15 |
Immunomedics Inc |
Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
|
|
US7906118B2
(en)
|
2005-04-06 |
2011-03-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
|
US8871446B2
(en)
|
2002-10-02 |
2014-10-28 |
California Institute Of Technology |
Microfluidic nucleic acid analysis
|
|
JP4959136B2
(ja)
*
|
2002-12-13 |
2012-06-20 |
イミューノメディクス、インコーポレイテッド |
細胞内で開裂可能な結合を有する免疫接合体
|
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
|
US7534427B2
(en)
*
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
|
US20040202666A1
(en)
*
|
2003-01-24 |
2004-10-14 |
Immunomedics, Inc. |
Anti-cancer anthracycline drug-antibody conjugates
|
|
CN1767860A
(zh)
*
|
2003-01-31 |
2006-05-03 |
免疫医疗公司 |
施用治疗和诊断剂的方法和组合物
|
|
KR100930353B1
(ko)
*
|
2003-03-06 |
2009-12-08 |
엘지전자 주식회사 |
디스크 플레이어의 접속요청 처리방법
|
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
WO2005014618A2
(en)
|
2003-08-08 |
2005-02-17 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
|
US20060228331A1
(en)
|
2003-10-10 |
2006-10-12 |
Novo Nordisk A/S |
IL-21 Derivatives and variants
|
|
MXPA06004199A
(es)
*
|
2003-10-17 |
2006-06-28 |
Novo Nordisk As |
Terapia en combinacion.
|
|
DE602004024921D1
(de)
*
|
2003-11-17 |
2010-02-11 |
Genentech Inc |
Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
|
|
US20110064754A1
(en)
*
|
2005-03-03 |
2011-03-17 |
Center For Molecular Medicine And Immunology |
Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
|
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8491914B2
(en)
*
|
2004-02-13 |
2013-07-23 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US20110020273A1
(en)
*
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
|
US8435539B2
(en)
*
|
2004-02-13 |
2013-05-07 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8562988B2
(en)
*
|
2005-10-19 |
2013-10-22 |
Ibc Pharmaceuticals, Inc. |
Strategies for improved cancer vaccines
|
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US7589063B2
(en)
|
2004-12-14 |
2009-09-15 |
Aplagen Gmbh |
Molecules which promote hematopoiesis
|
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
|
CA2599734C
(en)
*
|
2005-03-03 |
2014-01-28 |
Immunomedics, Inc. |
Humanized l243 antibodies
|
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
|
JP2006248978A
(ja)
*
|
2005-03-10 |
2006-09-21 |
Mebiopharm Co Ltd |
新規なリポソーム製剤
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
DK1874821T3
(da)
|
2005-04-26 |
2013-07-08 |
Trion Pharma Gmbh |
Kombination af antistoffer med glykokortikoider til behandling af kræft
|
|
US7531637B2
(en)
*
|
2005-05-06 |
2009-05-12 |
Zymogenetics, Inc. |
IL-31 monoclonal antibodies
|
|
WO2007101698A2
(en)
*
|
2006-03-09 |
2007-09-13 |
Aplagen Gmbh |
Modified molecules which promote hematopoiesis
|
|
US8524865B2
(en)
|
2006-05-30 |
2013-09-03 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
|
KR20150067395A
(ko)
|
2006-12-01 |
2015-06-17 |
메다렉스, 엘.엘.시. |
씨디22에 결합하는 인간 항체 및 이의 용도
|
|
EP2117558A4
(en)
*
|
2007-01-26 |
2013-04-03 |
Univ Colorado |
METHOD FOR MODULATING THE IMMUNO FUNCTION
|
|
RS53595B1
(sr)
|
2007-07-16 |
2015-02-27 |
Genentech, Inc. |
Anti-cd79b antitela i imunokonjugati i metode upotrebe
|
|
ES2528922T3
(es)
|
2007-07-16 |
2015-02-13 |
Genentech, Inc. |
Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
|
|
EP2215108A4
(en)
|
2007-10-23 |
2012-07-04 |
Univ Colorado |
COMPETITIVE INHIBITORS OF THE EXPRESSION OF THE CONSTANT CHAIN AND / OR THE ECTOPIC CLIP BINDING
|
|
JP5468015B2
(ja)
|
2008-01-08 |
2014-04-09 |
アクセリア ファーマシューティカルズ |
抗菌ペプチド系に対する作動薬
|
|
ES2796085T3
(es)
|
2008-01-15 |
2020-11-25 |
Univ Leland Stanford Junior |
Marcadores de células madre de leucemia mieloide aguda
|
|
US11072655B2
(en)
|
2008-01-15 |
2021-07-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Markers of acute myeloid leukemia stem cells
|
|
JP5547656B2
(ja)
|
2008-01-15 |
2014-07-16 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
Ｃｄ４７によって媒介される食作用を操作するための方法
|
|
IL287292B
(en)
|
2008-01-31 |
2022-09-01 |
Genentech Inc |
Cycteine engineering anti-cd79b antibodies and antibody-drug conjugates
|
|
KR20110014141A
(ko)
*
|
2008-03-20 |
2011-02-10 |
카롤러스 테라퓨틱스, 인코포레이티드 |
염증을 치료하는 방법
|
|
CA2716628A1
(en)
*
|
2008-03-24 |
2009-10-01 |
Carolus Therapeutics, Inc. |
Methods and compositions for treating atherosclerosis and related conditions
|
|
AU2009282830B2
(en)
*
|
2008-08-20 |
2013-11-28 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) vaccines for cancer therapy
|
|
WO2010056910A2
(en)
*
|
2008-11-12 |
2010-05-20 |
Carolus Therapeutics, Inc. |
Methods of treating cardiovascular disorders
|
|
US8217149B2
(en)
|
2008-12-09 |
2012-07-10 |
Genentech, Inc. |
Anti-PD-L1 antibodies, compositions and articles of manufacture
|
|
EP2198879A1
(en)
*
|
2008-12-11 |
2010-06-23 |
Institut Curie |
CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
|
|
EP3903829B1
(en)
|
2009-02-13 |
2023-05-03 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
|
EP2478110B1
(en)
|
2009-09-16 |
2016-01-06 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
CA2773978A1
(en)
*
|
2009-09-23 |
2011-03-31 |
Carolus Therapeutics, Inc. |
Methods of treating inflammation
|
|
CN102573902A
(zh)
*
|
2009-11-05 |
2012-07-11 |
分子医学和免疫学中心 |
用于基于亚单位的痘病毒疫苗的包含痘病毒衍生肽和针对抗原呈递细胞的抗体的免疫偶联物
|
|
ES2978177T3
(es)
|
2009-12-02 |
2024-09-06 |
Immunomedics Inc |
Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
|
|
CA2787054A1
(en)
*
|
2010-01-11 |
2011-07-14 |
Center For Molecular Medicine And Immunology |
Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
|
|
WO2011123428A1
(en)
*
|
2010-04-01 |
2011-10-06 |
Immunomedics, Inc. |
Antibody-based depletion of antigen-presenting cells and dendritic cells
|
|
DE102010026064A1
(de)
*
|
2010-06-30 |
2012-01-05 |
Siemens Aktiengesellschaft |
11C-markiertes Peptid zur Detektion eines krankhaften Gewebes
|
|
DE102010026063A1
(de)
*
|
2010-06-30 |
2012-01-05 |
Siemens Aktiengesellschaft |
11C-markiertes Peptid zur Detektion eines krankhaften Gewebes
|
|
CA2808211C
(en)
*
|
2010-08-17 |
2018-08-28 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
|
|
SG10201506959SA
(en)
|
2010-09-03 |
2015-10-29 |
Stemcentrx Inc |
Novel modulators and methods of use
|
|
WO2012094495A2
(en)
|
2011-01-05 |
2012-07-12 |
The Texas A&M University System |
Clip modulation for the treatment of mucosal diseases
|
|
MX350200B
(es)
*
|
2011-02-01 |
2017-08-30 |
Genmab As |
Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
|
|
US8673308B2
(en)
*
|
2011-02-23 |
2014-03-18 |
Als Therapy Development Institute |
Targeting of CD8+ T-lymphocytes to treat neurodegenerative diseases
|
|
CA2831572C
(en)
|
2011-05-02 |
2019-11-26 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
CA2842195A1
(en)
|
2011-07-18 |
2013-01-24 |
Immunomedics, Inc. |
Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death
|
|
BR112014010008A2
(pt)
|
2011-10-26 |
2018-09-04 |
Novartis Ag |
anticorpos monoclonais, seus usos e ácidos nucleicos
|
|
EA034989B1
(ru)
|
2011-10-28 |
2020-04-15 |
Тева Фармасьютикал Австралия Пти Лтд |
Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон
|
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
|
WO2013085893A1
(en)
|
2011-12-05 |
2013-06-13 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
|
WO2013173223A1
(en)
|
2012-05-15 |
2013-11-21 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
CA2876706A1
(en)
|
2012-06-14 |
2013-12-19 |
Ambrx, Inc. |
Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
|
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
GB201216649D0
(en)
*
|
2012-09-18 |
2012-10-31 |
Univ Birmingham |
Agents and methods
|
|
EP2905290B1
(en)
|
2012-10-05 |
2019-12-04 |
Kyowa Kirin Co., Ltd. |
Heterodimeric protein composition
|
|
DK2839860T3
(da)
|
2012-10-12 |
2019-06-17 |
Medimmune Ltd |
Pyrrolobenzodiazepiner og konjugater deraf
|
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
|
US20240139324A1
(en)
|
2012-12-13 |
2024-05-02 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
|
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
|
US12310958B2
(en)
|
2012-12-13 |
2025-05-27 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
US9107960B2
(en)
|
2012-12-13 |
2015-08-18 |
Immunimedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
|
DK2900277T3
(da)
|
2012-12-13 |
2022-04-04 |
Immunomedics Inc |
Doser af immunokonjugater af antistoffer og sn-38 til forbedret effektivitet og reduceret toksicitet
|
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
|
US8877202B2
(en)
|
2013-02-07 |
2014-11-04 |
Immunomedics, Inc. |
Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
|
|
WO2014127200A1
(en)
|
2013-02-15 |
2014-08-21 |
Immunomedics, Inc. |
Chimeric and humanized anti-histone antibodies
|
|
EP2774930A1
(en)
|
2013-03-07 |
2014-09-10 |
Aptenia S.R.L. |
Metallocene compounds and labeled molecules comprising the same for in vivo imaging.
|
|
ES2687439T3
(es)
|
2013-03-13 |
2018-10-25 |
Medimmune Limited |
Pirrolobenzodiazepinas y conjugados de las mismas
|
|
AU2014249243C1
(en)
|
2013-03-13 |
2019-08-08 |
Imaginab, Inc. |
Antigen binding constructs to CD8
|
|
CN103207277B
(zh)
*
|
2013-03-28 |
2015-04-15 |
中国人民解放军第二军医大学 |
一种人源性可溶型cd74蛋白的elisa检测试剂盒及检测方法
|
|
CA2909952C
(en)
|
2013-04-29 |
2021-10-12 |
Teva Pharmaceuticals Australia Pty Ltd. |
Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
|
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
WO2015067277A1
(en)
|
2013-11-07 |
2015-05-14 |
University Of Copenhagen |
Timp-1 binding partner
|
|
IL320281A
(en)
*
|
2013-12-25 |
2025-06-01 |
Daiichi Sankyo Co Ltd |
Anti-trop2 antibodies and methods for producing same
|
|
JP6655017B2
(ja)
|
2014-01-27 |
2020-02-26 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
Ｍｈｃクラスｉエピトープ送達ポリペプチド
|
|
WO2015126548A1
(en)
|
2014-02-21 |
2015-08-27 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to trop-2 expressing cells
|
|
CA2935748A1
(en)
|
2014-02-25 |
2015-09-03 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
|
EP3872090A1
(en)
*
|
2014-03-11 |
2021-09-01 |
Molecular Templates, Inc. |
Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions
|
|
HUE042829T2
(hu)
|
2014-04-03 |
2019-07-29 |
Igm Biosciences Inc |
Módosított J-lánc
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
US10351621B2
(en)
|
2014-06-24 |
2019-07-16 |
Immunomedics, Inc. |
Anti-histone therapy in acute kidney injury
|
|
WO2015200260A1
(en)
|
2014-06-24 |
2015-12-30 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
|
JP7080055B2
(ja)
|
2014-09-08 |
2022-06-03 |
ルタナ ゲーエムベーハー |
細胞の細胞質への分子の送達のための構築物
|
|
CN106687141A
(zh)
|
2014-09-10 |
2017-05-17 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其缀合物
|
|
CN104280553B
(zh)
*
|
2014-09-22 |
2016-06-08 |
中国人民解放军第二军医大学 |
一种小鼠源性可溶型cd74蛋白的elisa检测试剂盒及检测方法
|
|
EP3689910A3
(en)
|
2014-09-23 |
2020-12-02 |
F. Hoffmann-La Roche AG |
Method of using anti-cd79b immunoconjugates
|
|
JP6678941B2
(ja)
|
2014-10-07 |
2020-04-15 |
イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． |
抗体−薬物コンジュゲートのネオアジュバント使用
|
|
SG11201703251TA
(en)
|
2014-10-29 |
2017-05-30 |
Teva Pharmaceuticals Australia Pty Ltd |
INTERFERON α2B VARIANTS
|
|
IL284985B2
(en)
|
2015-02-18 |
2023-03-01 |
Enlivex Therapeutics R& D Ltd |
Combined immunotherapy and cytokine control therapy for cancer treatment
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
WO2016131856A1
(en)
*
|
2015-02-18 |
2016-08-25 |
F. Hoffmann-La Roche Ag |
Immunoconjugates for specific induction of t cell cytotoxicity against a target cell
|
|
PL3265575T3
(pl)
|
2015-03-04 |
2021-11-29 |
Igm Biosciences, Inc. |
Cząsteczki wiążące CD20 i ich zastosowania
|
|
CA2982452A1
(en)
|
2015-04-21 |
2016-10-27 |
Enlivex Therapeutics Ltd. |
Therapeutic pooled blood apoptotic cell preparations and uses thereof
|
|
JP6746845B2
(ja)
|
2015-04-22 |
2020-08-26 |
イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． |
循環ｔｒｏｐ−２陽性癌細胞の単離、検出、診断及び／または特徴付け
|
|
LT3303373T
(lt)
|
2015-05-30 |
2020-07-10 |
Molecular Templates, Inc. |
Deimunizuoto shiga toksino a subvieneto karkasai ir juos apimančios ląstelės taikinio molekulės
|
|
GB201511191D0
(en)
*
|
2015-06-25 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
T-cell epitopes for the immunotherapy of myeloma
|
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
|
WO2016210108A1
(en)
|
2015-06-25 |
2016-12-29 |
Immunomedics, Inc. |
Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
PL3316885T3
(pl)
|
2015-07-01 |
2021-12-06 |
Immunomedics, Inc. |
Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
|
|
CN108136012B
(zh)
|
2015-08-07 |
2022-10-04 |
伊麦吉纳博公司 |
靶向分子的抗原结合构建体
|
|
AU2016329197B2
(en)
|
2015-09-30 |
2021-01-21 |
Igm Biosciences, Inc. |
Binding molecules with modified J-chain
|
|
CN108463472A
(zh)
|
2015-09-30 |
2018-08-28 |
Igm生物科学有限公司 |
具有修饰的j-链的结合分子
|
|
EP3359194A4
(en)
|
2015-10-06 |
2019-04-24 |
Merck Sharp & Dohme Corp. |
ANTIBODY-ACTIVE CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS
|
|
CA3008102A1
(en)
*
|
2015-12-18 |
2017-06-22 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
US10869929B2
(en)
|
2016-01-29 |
2020-12-22 |
Merck Sharp & Dohme Corp. |
Phosphonate linkers and their use to facilitate cellular retention of compounds
|
|
CA3011372A1
(en)
|
2016-02-10 |
2017-08-17 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
|
US11730761B2
(en)
|
2016-02-18 |
2023-08-22 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
CN109310385A
(zh)
|
2016-04-27 |
2019-02-05 |
免疫医疗公司 |
抗trop-2-sn-38抗体药物缀合物用于检查点抑制剂复发/难治的肿瘤的疗法的功效
|
|
ES2877820T3
(es)
*
|
2016-08-01 |
2021-11-17 |
Health Research Inc |
Composiciones y métodos para la clonación rápida de receptores de células T
|
|
CN109862919A
(zh)
|
2016-10-11 |
2019-06-07 |
免疫医疗有限公司 |
抗体-药物缀合物联合免疫介导的治疗剂
|
|
IL302130A
(en)
|
2016-12-07 |
2023-06-01 |
Molecular Templates Inc |
Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
|
|
KR102590672B1
(ko)
|
2017-01-25 |
2023-10-18 |
몰레큘러 템플레이츠, 인코퍼레이션. |
탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
|
|
EP3600283A4
(en)
|
2017-03-27 |
2020-12-16 |
Immunomedics, Inc. |
TREATMENT OF TROP-2 EXPRESSIVE TRIPLE NEGATIVE BREAST CANCER WITH SACITUZUMAB GOVITECAN AND A RAD51 INHIBITOR
|
|
EP3606964A4
(en)
|
2017-04-03 |
2020-12-09 |
Immunomedics, Inc. |
SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
|
|
PE20251254A1
(es)
*
|
2017-05-24 |
2025-05-06 |
Novartis Ag |
Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
|
|
EP3796942A1
(en)
|
2018-05-23 |
2021-03-31 |
ADC Therapeutics SA |
Molecular adjuvant
|
|
US20210338834A1
(en)
|
2018-09-26 |
2021-11-04 |
Ascendis Pharma A/S |
Degradable hyaluronic acid hydrogels
|
|
CN111303293B
(zh)
*
|
2018-11-14 |
2022-08-30 |
杭州尚健生物技术有限公司 |
一种融合蛋白及其用途
|
|
US20230092679A1
(en)
|
2019-05-20 |
2023-03-23 |
Novartis Ag |
Mcl-1 inhibitor antibody-drug conjugates and methods of use
|
|
EP4058479A4
(en)
|
2019-11-15 |
2024-02-28 |
University of Tennessee Research Foundation |
MODIFIED IMMUNOLOBULINES FOR TARGETING AMYLOID DEPOSITS
|
|
US20230256114A1
(en)
|
2020-07-07 |
2023-08-17 |
Bionecure Therapeutics, Inc. |
Novel maytansinoids as adc payloads and their use for the treatment of cancer
|
|
WO2022008699A1
(en)
|
2020-07-09 |
2022-01-13 |
F. Hoffmann-La Roche Ag |
Concentrated compositions of proteins, their preparation and use thereof
|
|
CN116368154A
(zh)
|
2020-10-08 |
2023-06-30 |
阿菲姆德股份有限公司 |
三特异性结合剂
|
|
WO2022079211A1
(en)
|
2020-10-16 |
2022-04-21 |
Adc Therapeutics Sa |
Glycoconjugates
|
|
WO2022133169A1
(en)
|
2020-12-18 |
2022-06-23 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
US20250073349A1
(en)
|
2021-05-10 |
2025-03-06 |
Kawasaki Institute Of Industrial Promotion |
Antibody having reduced binding affinity for antigen
|
|
WO2022246433A1
(en)
|
2021-05-18 |
2022-11-24 |
University Of Tennessee Research Foundation |
Antibody-peptide fusion proteins for treating amyloid disorders
|
|
CN113238061B
(zh)
*
|
2021-07-09 |
2021-10-01 |
中南大学湘雅医院 |
以cd180阴性b细胞指示重症肌无力病情的试剂盒及应用
|
|
JP2024529381A
(ja)
|
2021-07-30 |
2024-08-06 |
アフィメド ゲーエムベーハー |
デュプレックスボディ
|
|
CN118043080A
(zh)
|
2021-08-13 |
2024-05-14 |
昆山新蕴达生物科技有限公司 |
一种基于微管抑制剂的抗体偶联药物
|
|
JP2024532295A
(ja)
|
2021-08-24 |
2024-09-05 |
クンシャン シンユンター バイオテック カンパニー，リミティド |
切断可能なリンカーを介して結合した抗体薬物複合体
|
|
IL312060A
(en)
|
2021-11-03 |
2024-06-01 |
Affimed Gmbh |
Bispecific CD16A binders
|
|
JP2024541058A
(ja)
|
2021-11-03 |
2024-11-06 |
ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． |
抗体の特異的共役
|
|
EP4445919A1
(en)
|
2021-12-09 |
2024-10-16 |
Kunshan Xinyunda Biotech Co., Ltd. |
Antibody-drug conjugate having improved affinity, and preparation method therefor and application thereof
|
|
WO2023225359A1
(en)
|
2022-05-20 |
2023-11-23 |
Novartis Ag |
Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
|
|
EP4570272A1
(en)
|
2022-08-10 |
2025-06-18 |
Kowa Company, Ltd. |
New drug complex
|
|
CN116139267A
(zh)
*
|
2023-01-28 |
2023-05-23 |
华中科技大学同济医学院附属同济医院 |
小鼠cd74单克隆抗体在制备治疗肿瘤药物中的应用
|
|
WO2025250969A1
(en)
*
|
2024-05-31 |
2025-12-04 |
Vertex Pharmaceuticals Incorporated |
Anti-cd74 antibodies, conjugates and uses thereof
|